Tectonic Therapeutic, Inc.
TECX
Rank in Stocks
#12949
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm... Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
Share Price
$21.89
Last synced: 2026-11-09
Market Cap
$427.94M
Change (1 day)
6.06%
Change (1 year)
15.33%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Tectonic Therapeutic, Inc. (TECX)
Category
Healthcare
EPS for Tectonic Therapeutic, Inc. (TECX)
EPS as of September 2026 TTM: $-4.63
According to Tectonic Therapeutic, Inc.'s latest financial reports, its current EPS (TTM) is $-4.63. At the end of 2025 the company had an EPS of $-4.05, a decrease compared to its 2024 EPS of $-3.93.
EPS history for Tectonic Therapeutic, Inc. from 2016 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-4.63 | 14.32% |
| 2025 | $-4.05 | 3.05% |
| 2024 | $-3.93 | -66.09% |
| 2023 | $-11.59 | -60.10% |
| 2022 | $-29.05 | -12.92% |
| 2021 | $-33.36 | -15.93% |
| 2020 | $-39.68 | 24.31% |
| 2019 | $-31.92 | 36.35% |
| 2018 | $-23.41 | 150.37% |
| 2017 | $-9.35 | 299.57% |
| 2016 | $-2.34 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -438.23% |
US
|
|
| $-7.07 | 52.70% |
US
|
|
| $-5.29 | 14.25% |
AU
|
|
| $12.88 | -378.19% |
BE
|
|
| $21.56 | -565.66% |
NL
|
Questions about Tectonic Therapeutic, Inc.'s earnings per share (EPS)
What is Tectonic Therapeutic, Inc.'s earnings per share (EPS)?
Tectonic Therapeutic, Inc.'s earnings per share (EPS) over the last twelve months is $-4.63, as of Sep 2026.
What was Tectonic Therapeutic, Inc.'s earnings per share (EPS) in 2025?
In 2025, Tectonic Therapeutic, Inc.'s earnings per share (EPS) was $-4.05, compared with $-3.93 in 2024.
How has Tectonic Therapeutic, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Tectonic Therapeutic, Inc.'s earnings per share (EPS) was highest in 2024 ($-3.93) and lowest in 2020 ($-39.68).
How does Tectonic Therapeutic, Inc.'s earnings per share (EPS) compare with similar companies?
Tectonic Therapeutic, Inc.'s earnings per share (EPS) ($-4.63) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.